Daily oral treatment with zibotentan, a blocker of the endothelin protein receptor, was found safe, and possibly may be able to improve kidney function in scleroderma patients with kidney disease, a Phase 2 trial shows. The study, “Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised…
News
Fewer than one in five scleroderma patients seek help from mental health services, an international study found. The patients most often turned to general practitioners as their providers of mental health care, followed by psychologists and psychiatrists. The study, “Mental health care use and associated factors in systemic…
Watermelon stomach, a condition in which the stomach lining bleeds, is an early and relatively common manifestation of systemic sclerosis (SSc) — especially among patients with diffuse disease — that is associated with worse quality of life, a study in Australia shows. Officially gastric antral vascular ectasia (GAVE), the…
The U.S. Food and Drug Administration (FDA) has cleared Thermo Fisher Scientific to market its blood tests for diagnosing scleroderma and systemic lupus erythematosus (SLE), two autoimmune diseases. “Autoimmune diseases can be a challenge to diagnose. Reliable and accurate laboratory tests that provide clinical clarity are essential…
The National Organization for Rare Disorders’ (NORD) “Living Rare, Living Stronger Patient and Family Forum” is back in person on June 26 for a day of learning and networking in Cleveland, Ohio. The event, which brings together the rare disease community, will take place at the InterContinental Cleveland Conference…
The immunosuppressant Rituximab may ease arthritis — an inflammation of the joints — in patients with long-standing systemic sclerosis (SSc), a small Turkish study found. Moreover, in some patients, skin and lung symptoms either remained stable or eased, the researchers also observed. “The factors and markers affecting the treatment…
June is Scleroderma Awareness Month, and the scleroderma community is working to increase awareness of this rare disease with several campaigns. In a video released at the start of the month, the National Scleroderma Foundation is asking everyone to “know scleroderma.” “To know scleroderma is to understand…
Autologous hematopoietic stem cell transplant (AHSCT) eases skin scarring in people with diffuse systemic sclerosis (SSc) by tweaking the levels of molecules involved in tissue remodeling and inflammation, a study from Brazil reported. The study, “Autologous hematopoietic stem cell transplantation promotes connective tissue remodeling in systemic sclerosis patients,” was…
Therapeutic plasma exchange may help ease digestive issues in people with limited systemic scleroderma (lcSSc), new research indicates. Edward Harris of the Scleroderma Education Project presented the findings at the American Society for Apheresis (ASFA) annual meeting in Philadelphia earlier this month, in a poster titled, “The Effects…
To kick off Scleroderma Awareness Month, the Scleroderma Research Foundation (SRF) will host a free online patient forum, Collaborating for a Cure, on June 1. The half-day forum will gather leaders from the medical and scientific community so that those who live with scleroderma, and their families and…
Recent Posts
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients
- On choosing medicine’s side effects over scleroderma progression
- Telerehabilitation improves hand mobility in scleroderma women
- Molecular pathway ID’d as key driver of scarring in scleroderma
- Limited hand function disrupts daily life for people living with SSc
- Coping with loss is part of living with scleroderma
- CAR T-cell therapy eases SSc symptoms, early trial data show
- Milk-derived particles may offer treatment path for SSc fibrosis